| Krunal J Mehta Md Inc | |
|
130 W Route 66 Suite 214 Glendora CA 91740-6249 | |
| (626) 335-4129 | |
| (626) 335-6177 |
| Full Name | Krunal J Mehta Md Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 130 W Route 66, Glendora, California |
| Authorized Official Name and Position | Krunal J Mehta (PRESIDENT) |
| Authorized Official Contact | 6263354129 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Krunal J Mehta Md Inc 130 W Route 66 Suite 214 Glendora CA 91740-6249 Ph: (626) 335-4129 | Krunal J Mehta Md Inc 130 W Route 66 Suite 214 Glendora CA 91740-6249 Ph: (626) 335-4129 |
| NPI Number | 1396063970 |
|---|---|
| Provider Enumeration Date | 05/06/2010 |
| Last Update Date | 07/31/2015 |
| Medicare PECOS PAC ID | 5698809853 |
|---|---|
| Medicare Enrollment ID | O20100810000957 |
News Archive
In a new publication from Cardiovascular Innovations and Applications; Xiao-lei Yin, Dong-xue Liang, Lu Wang, Jing Qiu, Zhi-yun Yang, Jian-zeng Dong and Zhao-yuan Ma from Tsinghua University, Beijing, China; Capital Medical University, Beijing, China and The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China analyze coronary angiography video interpolation methods to reduce x-ray exposure frequency based on deep learning.
A tiny medical device containing gold specks could boost the effects of cancer medication and reduce its harm, research suggests.
In previous studies, eye movements and vision were only affected at blood alcohol concentrations (BACs) approaching the legal limit for driving (0.08% BAC), in England, Wales and Northern Ireland.
ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396063970 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | A110016 (California) | Primary |
| Provider Name | Krunal J Mehta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982867602 PECOS PAC ID: 2668506825 Enrollment ID: I20100810001009 |
News Archive
In a new publication from Cardiovascular Innovations and Applications; Xiao-lei Yin, Dong-xue Liang, Lu Wang, Jing Qiu, Zhi-yun Yang, Jian-zeng Dong and Zhao-yuan Ma from Tsinghua University, Beijing, China; Capital Medical University, Beijing, China and The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China analyze coronary angiography video interpolation methods to reduce x-ray exposure frequency based on deep learning.
A tiny medical device containing gold specks could boost the effects of cancer medication and reduce its harm, research suggests.
In previous studies, eye movements and vision were only affected at blood alcohol concentrations (BACs) approaching the legal limit for driving (0.08% BAC), in England, Wales and Northern Ireland.
ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.
› Verified 1 days ago
News Archive
In a new publication from Cardiovascular Innovations and Applications; Xiao-lei Yin, Dong-xue Liang, Lu Wang, Jing Qiu, Zhi-yun Yang, Jian-zeng Dong and Zhao-yuan Ma from Tsinghua University, Beijing, China; Capital Medical University, Beijing, China and The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China analyze coronary angiography video interpolation methods to reduce x-ray exposure frequency based on deep learning.
A tiny medical device containing gold specks could boost the effects of cancer medication and reduce its harm, research suggests.
In previous studies, eye movements and vision were only affected at blood alcohol concentrations (BACs) approaching the legal limit for driving (0.08% BAC), in England, Wales and Northern Ireland.
ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first Tumor Paint product candidate, BLZ-100. The study, titled "A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer," will enroll up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or amelanotic melanoma.
› Verified 1 days ago
Burrows Family Practice, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1377 S Grand Ave, Glendora, CA 91740 Phone: 626-483-3348 Fax: 626-623-7258 | |
Valley Gastoenterology Consultants Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 415 W Carroll Ave, Suite 201, Glendora, CA 91741 Phone: 626-963-2490 Fax: 626-963-2495 | |
Marc Gutin M D Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 210 S Grand Ave, Suite 224, Glendora, CA 91741 Phone: 626-335-8094 Fax: 626-335-1874 | |
Nalini Singh Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 412 W Carroll Ave Ste 106, Glendora, CA 91741 Phone: 626-244-8170 | |
Devesh N Patel,md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 130 W Route 66, Suite 302, Glendora, CA 91740 Phone: 626-914-1514 Fax: 626-914-1505 | |
Krunal J Mehta Md Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 130 W Route 66 Ste 214, Glendora, CA 91740 Phone: 626-335-4129 Fax: 626-335-6177 | |
Nilesh N. Patel Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 130 W Route 66 Ste 302, Glendora, CA 91740 Phone: 626-914-1514 Fax: 626-914-1505 |